Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, April 25, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pharma Derivative

SAN JOSE - While underplaying serious side-effects of its major trial drug, Omontys (peginesatide), directors of Affymax dumped $12 million of their shares before the price sank by 84 percent, knocking $524 million off its market cap, shareholders say in a derivative complaint in Santa Clara County Court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...